Stocks News

LAST PRICE
23.9750
TODAY'S CHANGE (%)
Trending Down-1.7650 (-6.8570%)

Bid / Lots
23.9500/ 7
Ask / Lots
24.0000/ 7
Open / Previous Close
25.8900 / 25.7400
Day Range
Low 23.7700
High 25.8900
52 Week Range
Low 23.7700
High 53.1800
Volume
652,680
average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Nov 11, 2024
- Celldex Therapeutics to Present at Upcoming Investor Conferences, from 4:01PM ET on Monday Nov 11, 2024 by Dow Jones
  4:01PM ET on Monday Nov 11, 2024 by Dow Jones
  Companies Mentioned: CLDX
  
  Celldex Therapeutics to Present at Upcoming Investor Conferences
  
  HAMPTON, N.J., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in fireside chats at two upcoming conferences:
Nov 7, 2024
- DJ Celldex Therapeutics Price Target Maintained With a $80.00/Share by HC Wainwright & Co., from 3:25PM ET on Thursday Nov 07, 2024 by Dow Jones
  3:25PM ET on Thursday Nov 07, 2024 by Dow Jones
  Companies Mentioned: CLDX
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/CLDX/analyst-ratings
  
  (END) Dow Jones Newswires
  
  November 07, 2024 15:25 ET (20:25 GMT)
Nov 6, 2024
- -- Earnings Flash (CLDX) CELLDEX THERAPEUTICS Reports Q3 Revenue $3.2M, from 4:05PM ET on Wednesday Nov 06, 2024 by MT Newswires
  4:05PM ET on Wednesday Nov 06, 2024 by MT Newswires
  Companies Mentioned: CLDX
  04:05 PM EST, 11/06/2024 (MT Newswires) -- ...
- -- Earnings Flash (CLDX) CELLDEX THERAPEUTICS Posts Q3 Loss $-0.64, from 4:05PM ET on Wednesday Nov 06, 2024 by MT Newswires
  4:05PM ET on Wednesday Nov 06, 2024 by MT Newswires
  Companies Mentioned: CLDX
  04:05 PM EST, 11/06/2024 (MT Newswires) -- ...
- Celldex Reports Third Quarter 2024 Financial Results and Provides Corporate Update, from 4:01PM ET on Wednesday Nov 06, 2024 by Dow Jones
  4:01PM ET on Wednesday Nov 06, 2024 by Dow Jones
  Companies Mentioned: CLDX
  
  G&A Expenses: General and administrative (G&A) expenses were $10.1 million in the third quarter of 2024 and $28.3 million for the nine months ended September 30, 2024, compared to $8.2 million and $22.1 million for the comparable periods in 2023. The increase in G&A expenses was primarily due to an increase in stock-based compensation and barzolvolimab commercial planning expenses.

Today
- DJ Tarsus Pharmaceuticals Is Maintained at Neutral by Goldman Sachs, from 7 hours ago by Dow Jones
  7 hours ago by Dow Jones
  Companies Mentioned: TARS
Yesterday
- Oppenheimer Adjusts Tarsus Pharmaceuticals Price Target to $65 From $63, Maintains Outperform Rating, from 8:35AM ET on Thursday Nov 14, 2024 by MT Newswires
  8:35AM ET on Thursday Nov 14, 2024 by MT Newswires
  Companies Mentioned: TARS
- DJ Tarsus Pharmaceuticals Is Maintained at Outperform by Oppenheimer, from 8:26AM ET on Thursday Nov 14, 2024 by Dow Jones
  8:26AM ET on Thursday Nov 14, 2024 by Dow Jones
  Companies Mentioned: TARS
- DJ Viridian Therapeutics Is Maintained at Buy by HC Wainwright & Co., from 5:18AM ET on Thursday Nov 14, 2024 by Dow Jones
  5:18AM ET on Thursday Nov 14, 2024 by Dow Jones
  Companies Mentioned: VRDN
Nov 13, 2024
- Tarsus Pharmaceuticals Q3 Loss Narrows, Revenue Surges, from 4:35PM ET on Wednesday Nov 13, 2024 by MT Newswires
  4:35PM ET on Wednesday Nov 13, 2024 by MT Newswires
  Companies Mentioned: TARS
- -- Earnings Flash (TARS) TARSUS PHARMACEUTICALS Posts Q3 Revenue $48.1M, from 4:12PM ET on Wednesday Nov 13, 2024 by MT Newswires
  4:12PM ET on Wednesday Nov 13, 2024 by MT Newswires
  Companies Mentioned: TARS
- Tarsus Reports Third Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements, from 4:05PM ET on Wednesday Nov 13, 2024 by Dow Jones
  4:05PM ET on Wednesday Nov 13, 2024 by Dow Jones
  Companies Mentioned: TARS
- Press Release: Tarsus Reports Third Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements, from 4:05PM ET on Wednesday Nov 13, 2024 by Dow Jones
  4:05PM ET on Wednesday Nov 13, 2024 by Dow Jones
  Companies Mentioned: TARS
- Disc Medicine to Participate in Upcoming Investor Conferences, from 8:30AM ET on Wednesday Nov 13, 2024 by Dow Jones
  8:30AM ET on Wednesday Nov 13, 2024 by Dow Jones
  Companies Mentioned: IRON
- Tarsus Welcomes Kate Goodrich, M.D., MHS, to its Board of Directors, from 8:30AM ET on Wednesday Nov 13, 2024 by Dow Jones
  8:30AM ET on Wednesday Nov 13, 2024 by Dow Jones
  Companies Mentioned: TARS

Celldex Therapeutics Inc
NASDAQ:CLDXUnited States

Search Criteria

Nov 11, 2024

Celldex Therapeutics to Present at Upcoming Investor Conferences, from 4:01PM ET on Monday Nov 11, 2024 by Dow Jones

Nov 7, 2024

DJ Celldex Therapeutics Price Target Maintained With a $80.00/Share by HC Wainwright & Co., from 3:25PM ET on Thursday Nov 07, 2024 by Dow Jones

Nov 6, 2024

-- Earnings Flash (CLDX) CELLDEX THERAPEUTICS Reports Q3 Revenue $3.2M, from 4:05PM ET on Wednesday Nov 06, 2024 by MT Newswires

-- Earnings Flash (CLDX) CELLDEX THERAPEUTICS Posts Q3 Loss $-0.64, from 4:05PM ET on Wednesday Nov 06, 2024 by MT Newswires

Celldex Reports Third Quarter 2024 Financial Results and Provides Corporate Update, from 4:01PM ET on Wednesday Nov 06, 2024 by Dow Jones

Peers Headlines

Today

DJ Tarsus Pharmaceuticals Is Maintained at Neutral by Goldman Sachs, from 7 hours ago by Dow Jones

Yesterday

Oppenheimer Adjusts Tarsus Pharmaceuticals Price Target to $65 From $63, Maintains Outperform Rating, from 8:35AM ET on Thursday Nov 14, 2024 by MT Newswires

DJ Tarsus Pharmaceuticals Is Maintained at Outperform by Oppenheimer, from 8:26AM ET on Thursday Nov 14, 2024 by Dow Jones

DJ Viridian Therapeutics Is Maintained at Buy by HC Wainwright & Co., from 5:18AM ET on Thursday Nov 14, 2024 by Dow Jones

Nov 13, 2024

Tarsus Pharmaceuticals Q3 Loss Narrows, Revenue Surges, from 4:35PM ET on Wednesday Nov 13, 2024 by MT Newswires

-- Earnings Flash (TARS) TARSUS PHARMACEUTICALS Posts Q3 Revenue $48.1M, from 4:12PM ET on Wednesday Nov 13, 2024 by MT Newswires

Tarsus Reports Third Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements, from 4:05PM ET on Wednesday Nov 13, 2024 by Dow Jones

Press Release: Tarsus Reports Third Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements, from 4:05PM ET on Wednesday Nov 13, 2024 by Dow Jones

Disc Medicine to Participate in Upcoming Investor Conferences, from 8:30AM ET on Wednesday Nov 13, 2024 by Dow Jones

Tarsus Welcomes Kate Goodrich, M.D., MHS, to its Board of Directors, from 8:30AM ET on Wednesday Nov 13, 2024 by Dow Jones